ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Manuscript.pdf (1.32 MB)

Reducing hERG Toxicity Using hERG Classification Model and Fragment-growing Network

preprint
revised on 15.03.2021, 01:42 and posted on 15.03.2021, 10:54 by Yan Yang, Yanmin Zhang, Xingye Chen, Yi Hua, Guomeng Xing, Chenglong Deng, Li Liang, Tao Lu, Yadong Chen, Haichun Liu
Drug-induced cardiotoxicity has become one of the major reasons leading to drug withdrawal in past decades, which is closely related to the blockade of human Ether-a-go-go-related gene (hERG) potassium channel. Developing reliable hERG predicting model and optimizing model can greatly reduce the risk faced in drug discovery. In this study, we constructed eight hERG classification models, the best of which shows desirable generalization ability on low-similarity clinical compounds, as well as advantages in perceiving activity gap caused by small structural changes. Furthermore, we developed a hERG optimizer based on fragment grow strategy and explored its usage in four cases. After reinforcement learning, our model successfully suggests same or similar compounds as chemists’ optimization. Results suggest that our model can provide reasonable optimizing direction to reduce hERG toxicity when hERG risk is corresponding to lipophilicity, basicity, the number of rotatable bonds and pi-pi interactions. Overall, we demonstrate our model as a promising tool for medicinal chemists in hERG optimization attempts.

Funding

National Natural Science Foundation of China

National Natural Science Foundation of China

Find out more...

Natural Science Foundation of Jiangsu Province

State Key Laboratory Innovation Research and Cultivation Fund

“Double World-classes” Construction Program of China Pharmaceutical University

History

Email Address of Submitting Author

haichunliu@cpu.edu.cn

Institution

China Pharmaceutical University

Country

China

ORCID For Submitting Author

None

Declaration of Conflict of Interest

No

Version Notes

Version 1.2

Exports

ChemRxiv

Exports